A Phase 2/3, Interventional safety, pharmacokinetics, and efficacy, open-label, multi-center, single-arm study to investigate orally administered PF-07321332 (Nirmatrelvir)/Ritonavir in non-hospitalized symptomatic pediatric participants with COVID-19 who are at risk of progression to severe disease

Objective

Clinical Trial Details>>

Principal Investigator(s)
Jawad Nazir, MD

Clinical Trial Categories

  • Pediatrics
  • COVID-19
  • Pediatric
Sponsor(s)
Pfizer
Contact
Avera Research Institute at 605-504-3154
or ARI@Avera.org

Location

  • Avera Medical Group Infectious Disease Specialists
    6709 S Minnesota Avenue
    Suite 102
    Sioux Falls, SD 57108
    Main: 605-322-7250
  • Avera Research Institute — Sioux Falls
    6001 S Sharon Ave
    Sioux Falls, SD 57108
    Main: 605-504-3154